The rates and severity of Clostridium difficile infection (CDI) may be impacted by several factors, including antimicrobial use, other drug-prescribing factors, infection control practices, and the presence of a new strain of C. difficile that is more resistant to fluoroquinolones and associated with higher rates of morbidity and mortality. It is crucial for healthcare professionals to be aware of these factors and apply evidence-based practices for the prevention, diagnosis, and treatment of CDI.

To address the need for current education on CDI, Robert Michael Educational Institute LLC (RMEI) and Postgraduate Institute for Medicine (PIM) are jointly sponsoring a complimentary continuing education virtual lecture titled, "Clostridium difficile Infection: Tracking a Virulent Pathogen." The content of this virtual lecture is based on a live symposium that took place on June 10, 2009, during the 36th Association for Professionals in Infection Control and Epidemiology (APIC)  annual conference. This activity is supported by an educational grant from ViroPharma Incorporated.

Faculty for this program are experts in infection control and gastroenterology, including Stuart Johnson, MD, DTM&H; Dale N. Gerding, MD, FACP, FIDSA; Ciaran P. Kelly, MD; and Keith S. Kaye, MD, MPH.

 to access this complimentary continuing education virtual lecture.

News

HAIs

 health care-acquired infections (HAIs) page presents updates on the latest techniques and strategies in the never-ending battle between infection preventionists and HAIs. Focusing on the latest in medical literature, we also present perspectives from the top infection preventionists and other medical experts in the country about how to put the growing knowledge of HAIs into use in the everyday world of infection prevention. Articles and videos often focus on methods to contain and control pathogens and multidrug-resistant organisms from spreading within the health care system.